Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.60 |
| ▸ | AKT2 | P31751 | 10/20 | 0.60 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.60 |
| ▸ | FECH | P22830 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14161432 | 0.93 | AKT1 (0.62) | AKT1AKT2AKT3FECH | |
| SCHEMBL2027094 | 0.92 | AKT1 (0.59) | AKT1AKT2AKT3FECH | |
| SCHEMBL2035286 | 0.90 | AKT1 (0.55) | AKT1AKT2AKT3FECH | |
| SCHEMBL2026037 | 0.90 | AKT1 (0.65) | AKT1AKT2AKT3FECH | |
| SCHEMBL2025205 | 0.90 | AKT1 (0.58) | AKT1AKT2AKT3FECH | |
| SCHEMBL2027118 | 0.89 | AKT1 (0.54) | AKT1AKT2AKT3FECH | |
| SCHEMBL2028059 | 0.89 | AKT1 (0.63) | AKT1AKT2AKT3FECH | |
| SCHEMBL13762884 | 0.88 | AKT1 (0.56) | AKT1AKT2AKT3FECH | |
| SCHEMBL2026577 | 0.88 | AKT1 (0.57) | AKT1AKT2AKT3FECH | |
| SCHEMBL2030792 | 0.88 | AKT1 (0.66) | AKT1AKT2AKT3FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104669-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2009-09-30 | — | — | EP | claimed |
| WO-2008070016-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | claimed |
| WO-2013009535-A1 | IL-23 ANTAGONISTS FOR TREATMENT OR PREVENTION OF SKIN RASH ASSOCIATED WITH TREATMENT WITH P13K/AKT PATHWAY INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | WO | disclosed |
| US-8288407-B2 | Substituted naphthyridine compounds as inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288407-B2 | Substituted naphthyridine compounds as inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| EP-2104669-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2009-09-30 | — | — | EP | disclosed |
| US-7576209-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576209-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080161317-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080161317-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
| WO-2008070016-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161317-A1 | Inhibitors of Akt activity | PIK3CD, PIK3CA, PIK3CG | AKT1 12/4885AKT2 4/4885AKT3 8/4885 |
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | AKT1 12/4885AKT2 4/4885AKT3 8/4885 |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | AKT1 12/4885AKT2 4/4885AKT3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.